How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases
…in-person therapeutic index.” Initial indications for its lead TRPML1 program will likely be ALS and Parkinson’s disease, although Gill believes there is much wider potential. “There may be an opportunity…
